Sort
34,240 grants matching “atherosclerosis”
Cellular cholesterol movement and homeostasis
$300,000Yvonne Lange · Rush University Medical Center · R01 · FY2010 · HL
Are Cardioprotective Medications Effective in ESRD?
$300,000Theresa I. Shireman · University Of Kansas Medical Center · R01 · FY2008 · DK
ANGIOGENIC BYPASS &GENE THERAPY RESPONSE MECHANISMS
$300,000Evanston Northwestern Healthcare · R01 · FY2003 · HL
Cellular cholesterol movement and homeostasis
$300,000Yvonne Lange · Rush University Medical Center · R01 · FY2012 · HL
Structure and Mechanism of Maltose Transport
$300,000Jue Chen · Purdue University · R56 · FY2009 · GM
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** ATHEROSCLEROSIS IS A MAJOR CAUSE OF MORBIDITY AND MORTALITY IN THE INDUSTRIAL WORLD. MAMAKI, A SPECIES OF NETTLE ENDEMIC TO HAWAII, HAS BEEN USED BY NATIVES FOR CENTURIES FOR VARIOUS HEALTH BENEFITS. HOWEVER, ITS BIOACTIVE COMPONENTS AND THE MECHANISMS OF ACTION REMAIN LARGELY UNEXPLORED. WE HYPOTHESIZE THAT THE BIOACTIVE COMPOUNDS IN MAMAKI INHIBIT MONOCYTE ADHESION TO HUMAN AORTIC ENDOTHELIAL CELLS (HAECS) BY REGULATING CHEMOKINE AND ADHESION MOLECULE EXPRESSION, AN IMPORTANT STEP IN THE INITIATION AND PROGRESSION OF ATHEROSCLEROSIS. THE GOAL OF THIS STUDY IS TO IDENTIFY THE BIOACTIVE CONSTITUENTS OF MAMAKI LEAVES AND ELUCIDATE THE MECHANISMS OF ACTION. THE RESULTS OF THIS PROJECT COULD PROVIDE A BASIS FOR FUTURE CLINICAL INVESTIGATION INTO THE EFFICACY OF MAMAKI TEA OR ITS BIOACTIVE CONSTITUENTS IN PROTECTING AGAINST THE DEVELOPMENT OF VASCULAR DISEASES.
$300,000University Of North Carolina At Greensboro · · FY2024 · National Institute of Food and Agriculture
ANGIOGENIC BYPASS &GENE THERAPY RESPONSE MECHANISMS
$300,000Evanston Northwestern Healthcare · R01 · FY2002 · HL
Anti-inflammatory and Anti-diabetic Therapy for Metabolic Syndrome
$300,000Ridong Chen · Apt Therapeutics, Inc. · R43 · FY2020 · DK
Pathological Consequences of the Plasminogen System
$300,000University Of Notre Dame · R01 · FY2005 · HL
Cholesterol Ester Hydrolysis and Cholesterol Efflux
$300,000Virginia Commonwealth University · R01 · FY2005 · HL
APOL1, sickle cell trait and chronic kidney disease in African Americans
$300,000Nora Franceschini · Univ Of North Carolina Chapel Hill · R56 · FY2016 · DK
Novel Coronary Artery Vasodilator Development
$299,999John Frederick Schmedtje · Coeurative, Inc. · R43 · FY2023 · HL
Targeting lipid rafts for treatment of asthma
$299,989Kevin Bacon · Raft Pharmaceuticals, Llc · R41 · FY2020 · AI
Novel Wiring Catheter for Crossing Complex Chronic Total Occlusions
$299,975Nick Rydberg · Minnesota Healthsolutions Corporation · R43 · FY2022 · HL
Develop natural compound emodin as a novel therapy for calcific aortic valve disease
$299,953Mohamad Azhar · Acepre, Llc · R41 · FY2024 · HL
Targeting lipid rafts for treatment of asthma
$299,940Kevin Bacon · Raft Pharmaceuticals, Llc · R41 · FY2019 · AI
Manganese-based MRI contrast agent for quantitative myocardial perfusion imaging
$299,932Allen W Song · Laderx Llc · R41 · FY2024 · HL
Unique Anti-microbial Rinse to Reduce Oral Inflammation
$299,915Charles J Gauntt · Biomedical Development Corporation · R44 · FY2012 · HL
The roles of primary cilia in cardiovascular system
$299,910Surya Nauli · University Of Toledo · R01 · FY2012 · DK
The roles of primary cilia in cardiovascular system
$299,910Surya Nauli · University Of Toledo · R01 · FY2011 · DK
WALL SHEAR STRESS IN THE CARDIOVASCULAR SYSTEM
$299,908Pennsylvania State University-Univ Park · R01 · FY2000 · HL
AMPK, Metabolic and Inflammatory Stress and the Endothelial Cell
$299,887Neil B Ruderman · Boston Medical Center · P01 · FY2012 · HL
AMPK, Metabolic and Inflammatory Stress and the Endothelial Cell
$299,887Neil B Ruderman · Boston Medical Center · P01 · FY2011 · HL
SIRT1, Polyphenols, and Endothelial Oxidants
$299,885Richard A Cohen · Boston Medical Center · P01 · FY2011 · HL
SIRT1, Polyphenols, and Endothelial Oxidants
$299,885Richard A Cohen · Boston Medical Center · P01 · FY2012 · HL